Adaptation of an in vitro one-compartment pharmacodynamic chemostat for testing efficacy of ceftazidime against Burkholderia pseudomallei outside a BSL3 facility by Hana Farizah Zamri, Mohammad Ridhuan Mohd Ali, Ahmad Izzan Irfan Sha'ari, Nurul Husna Mohd Mazalan, Norazah Ahmad, Nur Asyura Nor Amdan, Nusaibah Abdul Rahim, Zakuan Zainy Deris

“…Non-clinical pharmacokinetic-pharmacodynamic (PKPD) models are crucial in the initial design of drug-dosage regimens and in drug development but has rarely been employed for testing high-risk organisms due to stringent handling procedures. …”
Get full text

The protoplast two-way fusions and fusant characteristics of Antrodia cinnamomea and Cordyceps militaris by Wei-Kuang Lai, Yang-Chang Wu, Tai-Sheng Yeh, Chun-Ren Hsieh, Yi-Hong Tsai, Chien-Kei Wei, Chi-Ying Li, Ying-Chen Lu, Fang-Rong Chang

Get full text

Caution when using network partners for target identification in drug discovery by Dandan Tan, Yiheng Chen, Yann Ilboudo, Kevin Y.H. Liang, Guillaume Butler-Laporte, J. Brent Richards

“…However, recent data indicate that leveraging human genetic evidence to identify and validate these targets significantly increases the likelihood of success in drug development. Two recent papers from Open Targets claimed that around half of US Food and Drug Administration-approved drugs had targets with direct human genetic evidence. …”
Get full text

Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study by Ting Lei, Yunjie Song, Zhiyi Shen, Yongqiang Shi, Cunyan Xia, Xu Deng, Wenyue Da, Yan Peng, Qing Li

Get full text

Assessment of Biological Activity, Total Phenolic Content, and Cytotoxicity of Ethyl Acetate Extracts from an Endophytic Fungus, Lasiodiplodia pseudotheobromae IBRL OS-64 by Mohd Taufiq Mat Jalil, Nurul Aili Zakaria, Mohd Fakharul Zaman Raja Yahya, Sharifah Aminah Syed Mohamad, Darah Ibrahim

“…Therefore, the present study suggests that the fraction extract could be an effective pharmaceutical agent and safe for drug development due to its low toxicity. …”
Get full text

Discovery of a heparan sulfate binding domain in monkeypox virus H3 as an anti-poxviral drug target combining AI and MD simulations by Bin Zheng, Meimei Duan, Yifen Huang, Shangchen Wang, Jun Qiu, Zhuojian Lu, Lichao Liu, Guojin Tang, Lin Cheng, Peng Zheng

“…This conserved domain, found across orthopoxviruses, was experimentally validated and shown to be critical for viral adhesion, making it an ideal target for antiviral drug development. Targeting this domain, we designed a protein inhibitor, which disrupted the H3-HS interaction, inhibited viral infection in vitro and viral replication in vivo, offering a promising antiviral candidate. …”
Get full text

Aspirin inhibits proteasomal degradation and promotes α-synuclein aggregate clearance through K63 ubiquitination by Jing Gao, Yang Liu, Chenfang Si, Rui Guo, Shouqiao Hou, Xiaosong Liu, Houfang Long, Di Liu, Daichao Xu, Zai-Rong Zhang, Cong Liu, Bing Shan, Christoph W. Turck, Kaiwen He, Yaoyang Zhang

“…These findings suggest two complementary mechanisms by which aspirin regulates the degradation of soluble and insoluble proteins, providing insights into its diverse pharmacological effects that can aid in future drug development efforts.…”
Get full text

A stretchable human lung‐on‐chip model of alveolar inflammation for evaluating anti‐inflammatory drug response by Clémentine Richter, Lorenz Latta, Daria Harig, Patrick Carius, Janick D. Stucki, Nina Hobi, Andreas Hugi, Paul Schumacher, Tobias Krebs, Alexander Gamrekeli, Felix Stöckle, Klaus Urbschat, Galia Montalvo, Franziska Lautenschläger, Brigitta Loretz, Alberto Hidalgo, Nicole Schneider‐Daum, Claus‐Michael Lehr

“…Abstract This study describes a complex human in vitro model for evaluating anti‐inflammatory drug response in the alveoli that may contribute to the reduction of animal testing in the pre‐clinical stage of drug development. The model is based on the human alveolar epithelial cell line Arlo co‐cultured with macrophages differentiated from the THP‐1 cell line, creating a physiological biological microenvironment. …”
Get full text

In silico identification of the anticataract target of βB2-crystallin from Phaseolus vulgaris: a new insight into cataract treatment by Sunday Amos Onikanni, Sunday Amos Onikanni, Adewale Oluwaseun Fadaka, Tran Nhat Phong Dao, Tran Nhat Phong Dao, Valens Munyembaraga, Valens Munyembaraga, Vincent Nyau, Nicole Remaliah Samantha Sibuyi, Morenike Grace Ajayi, Nguyen Thi Ai Nhung, Emmanuel Ejiofor, Basiru Olaitan Ajiboye, Basiru Olaitan Ajiboye, Minh Hoang Le, Hen-Hong Chang, Hen-Hong Chang, Hen-Hong Chang

Get full text

Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge by M. Biddle, P. Stylianou, M. Rekas, A. Wright, J. Sousa, D. Ruddy, M. I. Stefana, K. Kmiecik, A. Bandrowski, R.A. Kahn, C. Laflamme, E. M. Krockow, H.S. Virk

“…Yet many antibodies used in research do not recognize their intended target, or recognize additional molecules, compromising the integrity of research findings and leading to waste of resources, lack of reproducibility, failure of research projects, and delays in drug development. Researchers frequently use antibodies without confirming that they perform as intended in their application of interest. …”
Get full text

Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals by Sophie Tourdot, Daniel Baltrunkonis, Sofie Denies, Viswanath Devanarayan, Joanna Grudzinska-Goebel, Arno Kromminga, Gregor P. Lotz, Laurent Malherbe, Lydia Michaut, Karin N. Weldingh, Joao A. Pedras-Vasconcelos, Laura. I. Salazar-Fontana, Sebastian Spindeldreher, Zuben Sauna, Veerle Snoeck, Daniela Verthelyi, Daniel Kramer

“…Health authorities ask that a thorough immunogenicity risk assessment be conducted during drug development to incorporate an appropriate monitoring and mitigation plan in clinical studies. …”
Get full text

Analysis of the role of acetylation in Giardia lamblia and the giardicidal potential of garcinol by Rocío G. Patolsky, Jerónimo Laiolo, Jerónimo Laiolo, Luciano Díaz-Pérez, Gabriel Luna Pizarro, Gonzalo F. Mayol, María C. Touz, Constanza Feliziani, Andrea S. Rópolo

“…Significantly, garcinol prevented parasite recrudescence after treatment withdrawal.DiscussionThese results demonstrate that acetylation is essential for trophozoite survival and highlight the natural histone acetyltransferase inhibitor garcinol as a potential candidate for drug development against giardiasis, considering its giardicidal activity.…”
Get full text

Identification of macrophage polarisation and mitochondria-related biomarkers in diabetic retinopathy by Weifeng Liu, Bin Tong, Jian Xiong, Yanfang Zhu, Hongwei Lu, Haonan Xu, Xi Yang, Feifei Wang, Peng Yu, Yunwei Hu

“…Conclusion This study identified two biomarkers (PTAR1 and SLC25A34) which explore the pathogenesis of DR and provide reference targets for drug development.…”
Get full text

Application of Computer Simulation in Exploring the Effects of <italic>Achyranthis Bidentatae Radix</italic> on Simultaneously Treating Wei Syndrome and Bi Syndrome of Osteoarthrit... by Chunsong ZHENG, Hongzhi YE, Jinxia YE, Changlong FU

“…This could provide a basis for Niuxi therapeutic for OA and new drug development from Niuxi.…”
Get full text

Personalized prediction of anticancer potential of non-oncology drugs through learning from genome derived molecular pathways by Xiaobao Dong, Huanhuan Liu, Ting Tong, Liuxing Wu, Jianhua Wang, Tianyi You, Yongjian Wei, Xianfu Yi, Hongxi Yang, Jie Hu, Haitao Wang, Xiaoyan Wang, Mulin Jun Li

“…However, the high cost of drug development limits our ability to translate this knowledge into precise treatments. …”
Get full text

A Simple Machine Learning-Based Quantitative Structure–Activity Relationship Model for Predicting pIC₅₀ Inhibition Values of FLT3 Tyrosine Kinase by Jackson J. Alcázar, Ignacio Sánchez, Cristian Merino, Bruno Monasterio, Gaspar Sajuria, Diego Miranda, Felipe Díaz, Paola R. Campodónico

“…<b>Conclusions:</b> These results represent a significant advancement in the field of FLT3 inhibitor discovery, offering a reliable, practical, and efficient approach for early-stage drug development, potentially accelerating the creation of targeted therapies for AML.…”
Get full text

Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks by Elena Díaz-Santiago, Aurelio A. Moya-García, Jesús Pérez-García, Raquel Yahyaoui, Raquel Yahyaoui, Christine Orengo, Florencio Pazos, James R. Perkins, James R. Perkins, James R. Perkins, Juan A. G. Ranea, Juan A. G. Ranea, Juan A. G. Ranea, Juan A. G. Ranea

“…They also include adverse side effects, such as blurred vision being linked with tetracaine.DiscussionThis work represents an important advance in our understanding of how drugs cause intended and adverse side effects through their action on disease causing genes and has potential applications for drug development and repositioning.…”
Get full text

AxiWorm: a new tool using YOLOv5 to test antiparasitic drugs against Trichinella spiralis by Javier Sánchez-Montejo, Miguel Marín, María Alejandra Villamizar-Monsalve, María del Carmen Vieira, Belén Vicente, Rafael Peláez, Julio López-Abán, Antonio Muro

“…Abstract Background-Objective Trichinella spiralis drug development and control need an objective high throughput system to assess first stage larvae (L1) viability. …”
Get full text

Harnessing Non-Antibiotic Strategies to Counter Multidrug-Resistant Clinical Pathogens with Special Reference to Antimicrobial Peptides and Their Coatings by Shyam Kumar Mishra, Tanzina Akter, Umme Laila Urmi, George Enninful, Manjulatha Sara, Jiawei Shen, Dittu Suresh, Liangjun Zheng, Elias Shiferaw Mekonen, Binod Rayamajhee, Francesco M. Labricciosa, Massimo Sartelli, Mark Willcox

“…While these peptides hold significant promise, their application in mainstream drug development is hindered by challenges such as low bioavailability and potential toxicity. …”
Get full text

Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model by Xing Tu, Zixing Zou, Jiahui Li, Simiao Zeng, Zhengchao Luo, Gen Li, Yuanxu Gao, Kang Zhang, Jing Ni

“…AI-driven drug screening techniques have the potential to greatly accelerate drug development. A compound called HG9-91-01, identified using AI methods, exerted neuroprotective effects in acute glaucoma. …”
Get full text